Journal of perinatology : official journal of the California Perinatal Association · 2026
Prevalence and safety of diazoxide in the neonatal intensive care unit.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Collins Lucas C, Daniel Katherine B, Tolia Veeral N, Parikh Pratik, Gray Keyaria D, Greenberg Rachel G
Аннотация
OBJECTIVE: Diazoxide is used to treat infants with persistent hyperinsulinemic hypoglycemia. While recent studies have highlighted its adverse effects and variable usage, further characterization is needed. We report the demographic and clinical characteristics of infants exposed to diazoxide across NICUs.
STUDY DESIGN: Cohort study including infants born 24-41 weeks gestation and admitted to 345 NICUs from 2017-2022. Comparisons were made between hypoglycemic infants exposed to diazoxide and those not, collecting data on adverse events and additional therapies.
RESULTS: Among 545,065 infants, 22% were diagnosed with hypoglycemia, and 0.16% were exposed to diazoxide. Diazoxide use remained stable, with variability across NICUs (0-16%). Among infants exposed to diazoxide, 13% started new diuretic courses, 10% had new oxygen supplementation, and 3% needed ventilator support.
CONCLUSIONS: Diazoxide use in NICUs has remained stable over time. Although some infants received additional therapies, namely diuretics, most were able to discontinue diazoxide prior to discharge.
STUDY DESIGN: Cohort study including infants born 24-41 weeks gestation and admitted to 345 NICUs from 2017-2022. Comparisons were made between hypoglycemic infants exposed to diazoxide and those not, collecting data on adverse events and additional therapies.
RESULTS: Among 545,065 infants, 22% were diagnosed with hypoglycemia, and 0.16% were exposed to diazoxide. Diazoxide use remained stable, with variability across NICUs (0-16%). Among infants exposed to diazoxide, 13% started new diuretic courses, 10% had new oxygen supplementation, and 3% needed ventilator support.
CONCLUSIONS: Diazoxide use in NICUs has remained stable over time. Although some infants received additional therapies, namely diuretics, most were able to discontinue diazoxide prior to discharge.